203 related articles for article (PubMed ID: 22027536)
41. Mechanism of inhibition of cell proliferation by Vinca alkaloids.
Jordan MA; Thrower D; Wilson L
Cancer Res; 1991 Apr; 51(8):2212-22. PubMed ID: 2009540
[TBL] [Abstract][Full Text] [Related]
42. New semisynthetic vinca alkaloids: chemical, biochemical and cellular studies.
Orosz F; Comin B; Raïs B; Puigjaner J; Kovács J; Tárkányi G; Acs T; Keve T; Cascante M; Ovádi J
Br J Cancer; 1999 Mar; 79(9-10):1356-65. PubMed ID: 10188876
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and SAR of vinca alkaloid analogues.
Voss ME; Ralph JM; Xie D; Manning DD; Chen X; Frank AJ; Leyhane AJ; Liu L; Stevens JM; Budde C; Surman MD; Friedrich T; Peace D; Scott IL; Wolf M; Johnson R
Bioorg Med Chem Lett; 2009 Feb; 19(4):1245-9. PubMed ID: 19147348
[TBL] [Abstract][Full Text] [Related]
44. QM and QM/MD simulations of the Vinca alkaloids docked to tubulin.
Kelly EB; Tuszynski JA; Klobukowski M
J Mol Graph Model; 2011 Sep; 30():54-66. PubMed ID: 21798777
[TBL] [Abstract][Full Text] [Related]
45. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.
Kavallaris M; Tait AS; Walsh BJ; He L; Horwitz SB; Norris MD; Haber M
Cancer Res; 2001 Aug; 61(15):5803-9. PubMed ID: 11479219
[TBL] [Abstract][Full Text] [Related]
46. Tubulin-interacting agents. Epilogue.
Fahy J; Hill BT
Curr Pharm Des; 2001 Sep; 7(13):1297-301. PubMed ID: 11472269
[TBL] [Abstract][Full Text] [Related]
47. The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity.
Wieczorek M; Tcherkezian J; Bernier C; Prota AE; Chaaban S; Rolland Y; Godbout C; Hancock MA; Arezzo JC; Ocal O; Rocha C; Olieric N; Hall A; Ding H; Bramoullé A; Annis MG; Zogopoulos G; Harran PG; Wilkie TM; Brekken RA; Siegel PM; Steinmetz MO; Shore GC; Brouhard GJ; Roulston A
Sci Transl Med; 2016 Nov; 8(365):365ra159. PubMed ID: 27856798
[TBL] [Abstract][Full Text] [Related]
48. Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine.
Estève MA; Carré M; Bourgarel-Rey V; Kruczynski A; Raspaglio G; Ferlini C; Braguer D
Mol Cancer Ther; 2006 Nov; 5(11):2824-33. PubMed ID: 17121929
[TBL] [Abstract][Full Text] [Related]
49. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
[TBL] [Abstract][Full Text] [Related]
50. Vinflunine: review of a new vinca alkaloid and its potential role in oncology.
Ng JS
J Oncol Pharm Pract; 2011 Sep; 17(3):209-24. PubMed ID: 20584744
[TBL] [Abstract][Full Text] [Related]
51. [Thermodynamics of calmodulin and tubulin binding to the vinca-alkaloid vinorelbine].
Tsvetkov FO; Kulikova AA; Devred F; Zerniĭ EIu; Lafitte D; Makarov AA
Mol Biol (Mosk); 2011; 45(4):697-702. PubMed ID: 21954603
[TBL] [Abstract][Full Text] [Related]
52. [Antimitotic agents].
Fukuoka K; Saijo N
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1519-25. PubMed ID: 9309150
[TBL] [Abstract][Full Text] [Related]
53. Targeting microtubules for cancer chemotherapy.
Zhou J; Giannakakou P
Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262
[TBL] [Abstract][Full Text] [Related]
54. Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line.
Lobert S; Fahy J; Hill BT; Duflos A; Etievant C; Correia JJ
Biochemistry; 2000 Oct; 39(39):12053-62. PubMed ID: 11009620
[TBL] [Abstract][Full Text] [Related]
55. Vinflunine: a fluorinated vinca alkaloid for bladder cancer therapy.
Gerullis H
Drugs Today (Barc); 2011 Jan; 47(1):17-25. PubMed ID: 21373647
[TBL] [Abstract][Full Text] [Related]
56. Nanosolvated microtubule-modulating chemotherapeutics: a case-to-case study.
Jain V; Jain B; Tiwari P; Saini J; Jain UK; Pandey RS; Kumar M; Katare OP; Chandra R; Madan J
Anticancer Drugs; 2013 Apr; 24(4):327-36. PubMed ID: 23411683
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and evaluation of hybrid molecules targeting the vinca domain of tubulin.
Gherbovet O; Sánchez-Murcia PA; García Alvarez MC; Bignon J; Thoret S; Gago F; Roussi F
Org Biomol Chem; 2015 Mar; 13(10):3144-54. PubMed ID: 25634805
[TBL] [Abstract][Full Text] [Related]
58. In situ response to vinka alkaloids by microtubules in cultured post-implanted mouse embryos.
Meininger V; Binet S; Chaineau E; Fellous A
Biol Cell; 1990; 68(1):21-9. PubMed ID: 2180513
[TBL] [Abstract][Full Text] [Related]
59. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.
Dumontet C; Sikic BI
J Clin Oncol; 1999 Mar; 17(3):1061-70. PubMed ID: 10071301
[TBL] [Abstract][Full Text] [Related]
60. Stathmin potentiates vinflunine and inhibits Paclitaxel activity.
Malesinski S; Tsvetkov PO; Kruczynski A; Peyrot V; Devred F
PLoS One; 2015; 10(6):e0128704. PubMed ID: 26030092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
